Table 1 Patients’ characteristics
| Â | Overall cohort (n = 72) | Peritoneal carcinomatosis vs. no peritoneal carcinomatosis (PC) | ||
|---|---|---|---|---|
PC cohort (n = 39) | No PC cohort (n = 33) | p value | ||
Demographics | ||||
 Sex, n (%) |  |  |  | .502 |
  Male | 38 (52.8) | 22 (56.4) | 16 (48.5) |  |
  Female | 34 (47.2) | 17 (43.6) | 17 (51.5) |  |
 Age (years) | 66 (58–74) | 66 (57–74) | 65 (59–74) | .591 |
 BMI (kg/m2) | 24 (21–26) | 23 (21–26) | 24 (21–27) | .635 |
 ASA, n (%) |  |  |  | .654 |
  I | 0 | 0 | 0 |  |
  II | 19 (26.4) | 12 (30.8) | 7 (21.2) |  |
  III | 45 (62.5) | 23 (59.0) | 22 (66.7) |  |
  IV | 8 (11.1) | 4 (10.3) | 4 (12.1) |  |
  V | 0 |  | 0 |  |
Tumor characteristics | ||||
 Primary tumor, n (%) |  |  |  | .324 |
  Pancreatic adenocarcinoma | 42 (58.3) | 18 (46.2) | 24 (72.7) |  |
  Cholangiocellular carcinoma | 10 (13.9) | 8 (20.5) | 2 (6.1) |  |
  Gastric adenocarcinoma | 5 (6.9) | 3 (7.7) | 2 (6,1) |  |
  Intestinal carcinoma | 3 (4.2) | 2 (5.1) | 1 (3.0) |  |
  Colorectal carcinoma | 6 (8.3) | 4 (10.3) | 2 (6.1) |  |
  Renal cell carcinoma | 2 (2.8) | 1 (2.6) | 1 (3.0) |  |
  Transitional cell carcinoma | 1 (1.4) | 1 (2.6) | 0 |  |
  Mammarian carcinoma | 2 (2.8) | 2 (5.1) | 0 |  |
  Ovarian cancer | 1 (1.4) | 0 | 1 (3.0) |  |
 Synchronous/metachronous PC, n (%) |  |  |  |  |
  Synchronous PC | n.a. | 20 (51.3) | n.a. |  |
  Metachronous PC | n.a. | 19 (48.7) | n.a. |  |
 Distant metastasis, n (%) |  |  |  | .132 |
  Yes | 24 (33.3) | 10 (25.6) | 14 (42.4) |  |
  No | 48 (66.7) | 29 (74.4) | 19 (57.6) |  |
 Preoperative chemotherapy, n (%) |  |  |  | .776 |
  Yes | 10 (13.9) | 5 (12.8) | 5 (15.2) |  |
  No | 62 (86.1) | 34 (87.2) | 28 (84.8) |  |
Clinical chemistry | ||||
 Sodium (mmol/l) | 139 (136–141) | 139 (136–142) | 138 (136–141) | .536 |
 Hemoglobin (g/dl) | 10.6 (9.3–12.1) | 11.2 (9.0–12.7) | 10.2 (9.4–11.7) | .235 |
 Platelet count (nl) | 242 (198–355) | 250 (201–341) | 215 (195–416) | .739 |
 Total bilirubin (mg/dl) | 0.6 (0.4–2.0) | 0.59 (0.37–1.42) | 0.76 (0.44–3.81) | .235 |
 Prothrombin time (%) | 87 (77–98) | 89 (76–98) | 85 (76–98) | .773 |
 INR | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) | .874 |
 Albumin (g/l) | 32 (29–39) | 34 (28–38) | 31 (28–39) | .394 |
 Creatinine (mg/dl) | 0.8 (0.6–1.0) | 0.9 (0.6–1.1) | 0.7 (0.6–0.9) | .230 |
 CRP (mg/l) | 29 (11–56) | 25 (8–51) | 31 (13–81) | .317 |
Operative data | ||||
 Laparoscopic surgery, n (%) | 2 (2.8) | 0 | 2 (6.1) | .119 |
 Concomitant hepaticojejunostomy, n (%) | 26 (36.1) | 10 (25.6) | 16 (48.5) | .044 |
 Operative procedure, n (%) |  |  |  | .831 |
  Antecolic approach | 6 (8.3) | 3 (7.7) | 3 (9.1) |  |
  Retrocolic approach | 66 (91.7) | 36 (92.3) | 30 (90.9) |  |
 Operation time (min) | 170 (128–214) | 160 (113–215) | 192 (150–216) | .124 |
 Intraoperative blood transfusion (U) | 0 | 0 | 0 (0–2) | .817 |
 Intraoperative fresh frozen plasma (U) | 0 | 0 | 0 | .108 |
Postoperative data | ||||
 Intensive care, days | 1 (0–2) | 1 (0–2) | 1 (0–3) | .240 |
 Hospitalization, days | 13 (9–18) | 13 (10–20) | 12 (9–17) | .392 |
 PBD*, n (%) | 6 (13.0) | 5 (17.2) | 1 (5.9) | .270 |
 Postoperative complications, n (%) |  |  |  | .381 |
  No complications | 23 (31.9) | 13 (33.3) | 10 (30.3) |  |
  Clavien-Dindo I | 8 (11.1) | 4 (10.3) | 4 (12.1) |  |
  Clavien-Dindo II | 20 (27.8) | 8 (20.5) | 12 (36.4) |  |
  Clavien-Dindo IIIa | 4 (5.6) | 2 (5.1) | 2 (6.1) |  |
  Clavien-Dindo IIIb | 5 (6.9) | 2 (5.1) | 3 (9.1) |  |
  Clavien-Dindo IVa | 1 (1.4) | 1 (2.6) | 0 |  |
  Clavien-Dindo IVb | 0 | 0 | 0 |  |
  Clavien-Dindo V | 11 (15.3) | 9 (23.1) | 2 (6.1) |  |
 In-house mortality, n (%) | 11 (15.3) | 9 (23.1) | 2 (6.1) | .046 |
 Anastomotic stenosis, n (%) | 2 (2.8) | 1 (2.6) | 1 (3) | .905 |
 Anastomotic leakage, n (%) | 2 (2.8) | 2 (5.1) | 0 | .187 |
 Delayed gastric emptying, n (%) | 18 (25.0) | 13 (33.3) | 5 (15.2) | .076 |
 Paralytic ileus, n (%) | 12 (16.7) | 9 (23.1) | 3 (9.1) | .113 |
 Pneumonia, n (%) | 11 (15.3) | 7 (17.9) | 4 (12.1) | .493 |